Literature DB >> 412531

Antithrombin Pittsburgh: an alpha1-antitrypsin variant causing hemorrhagic disease.

J H Lewis, R M Iammarino, J A Spero, U Hasiba.   

Abstract

A 10-year-old boy had a severe lifelong hemorrhagic disorder that had necessitated more than 50 hospitalizations. Laboratory examination showed prolonged bleeding, clotting, partial thromboplastin, prothrombin, and thrombin times. These findings were due to a potent inhibitor of the thrombin-fibrinogen reaction. This inhibitor was similar to heparin in that it acted immediately and did not interfere with the coagulant activities of certain venoms. It differed from heparin in not being adsorbed to barium citrate or neutralized by protamine sulfate. The inhibitory effect was found in the alpha1-globulin fraction. It was identified immunologically and functionally as a double-banded alpha1-antitrypsin of a previously unreported phenotype. The inhibitory effects were depressed by trypsin and heterologous anti-alpha1-antitrypsin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 412531

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Human mesotrypsin exhibits restricted S1' subsite specificity with a strong preference for small polar side chains.

Authors:  Edit Szepessy; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2006-06-05       Impact factor: 5.542

2.  Alpha1-antitrypsin and the maintenance of hemostatic balance.

Authors:  Joseph Emmerich
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

3.  The Rheumatoid Arthritis-Associated Citrullinome.

Authors:  Ronak Tilvawala; Son Hong Nguyen; Aaron J Maurais; Venkatesh V Nemmara; Mitesh Nagar; Ari J Salinger; Sunil Nagpal; Eranthie Weerapana; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2018-04-05       Impact factor: 8.116

Review 4.  Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.

Authors:  Benjamin M Scott; William P Sheffield
Journal:  Protein Sci       Date:  2019-12-09       Impact factor: 6.725

5.  Recombinant alpha 1-antitrypsin Pittsburgh attenuates experimental gram-negative septicemia.

Authors:  R W Colman; D N Flores; R A De La Cadena; C F Scott; L Cousens; P J Barr; I B Hoffman; F Kueppers; D Fisher; S Idell
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

6.  Serpin targets in hemostasis/kinin formation.

Authors:  Alvin H Schmaier
Journal:  Blood       Date:  2019-11-07       Impact factor: 22.113

7.  Met 358 to Arg mutation of alpha 1-antitrypsin associated with protein C deficiency in a patient with mild bleeding tendency.

Authors:  D Vidaud; J Emmerich; M Alhenc-Gelas; J Yvart; J N Fiessinger; M Aiach
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

8.  Cloning, structure and expression of cDNA for mouse contrapsin and a related protein.

Authors:  K Ohkubo; S Ogata; Y Misumi; N Takami; H Sinohara; Y Ikehara
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

9.  Alpha1-antitrypsin Pittsburgh in a family with bleeding tendency.

Authors:  Baolai Hua; Liankai Fan; Yan Liang; Yongqiang Zhao; Edward G D Tuddenham
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

10.  Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf.

Authors:  C F Scott; R W Carrell; C B Glaser; F Kueppers; J H Lewis; R W Colman
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.